Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity : a descriptive study among the Arabic population
المؤلفون المشاركون
Nashwan, Abd al-Qadir J.
Yusuf, Zuhayb
Ata, Fatin
Zahir, Fatimah Z.
Babakr, Anas Muhammad
Faruqi, Amir Ali
al-Hayyari, Musa Ahmad
al-Buzum, Adil Isam
Muhammad, Ahmad Hatim
Yasin, Muhammad A.
المصدر
العدد
المجلد 2022، العدد 3 (31 ديسمبر/كانون الأول 2022)، ص ص. 1-9، 9ص.
الناشر
تاريخ النشر
2022-12-31
دولة النشر
قطر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management.
The response rate for Rituximab is variable in different populations ranging from 30% to 90%.
The adverse effects of rituximab in patients with ITP range from infusion site reactions to the reactivation of hepatitis B virus and progressive multifocal leukoencephalopathy and interpopulation variation.
Methods: We conducted a single-center, retrospective study in Qatar's National Center for Cancer Care & Research.
The study included patients with chronic refractory ITP who received rituximab as second-line therapy.
Descriptive and summary statistics were used to describe the sociodemographic parameters of the study cohort.
Results: Of the 41 patients with chronic ITP, 26 were Arabs, 12 were Asians, and 3 were of other ethnicities.
Rituximab was associated with an overall response rate of 80.4%.
Arabic patients had the highest clinical response (84.6%) among the ethnicities with the lowest adverse effects (11.5%).
Asians had a response rate of 66.6%, and adverse effects were seen in 16.7% of the patients.
Conclusions: In chronic refractory ITP, rituximab appears to have a better clinical response in the Arabic population with minimal toxicity than in other ethnicities.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ata, Fatin& Yusuf, Zuhayb& Zahir, Fatimah Z.& Babakr, Anas Muhammad& Faruqi, Amir Ali& al-Hayyari, Musa Ahmad…[et al.]. 2022. Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity : a descriptive study among the Arabic population. Qatar Medical Journal،Vol. 2022, no. 3, pp.1-9.
https://search.emarefa.net/detail/BIM-1437634
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ata, Fatin…[et al.]. Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity : a descriptive study among the Arabic population. Qatar Medical Journal No. 3 (2022), pp.1-9.
https://search.emarefa.net/detail/BIM-1437634
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ata, Fatin& Yusuf, Zuhayb& Zahir, Fatimah Z.& Babakr, Anas Muhammad& Faruqi, Amir Ali& al-Hayyari, Musa Ahmad…[et al.]. Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity : a descriptive study among the Arabic population. Qatar Medical Journal. 2022. Vol. 2022, no. 3, pp.1-9.
https://search.emarefa.net/detail/BIM-1437634
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 8-9
رقم السجل
BIM-1437634
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر